Skip to main content

7 Result(s)

within Hema Mistry Remove this filter Health Economics Remove this filter

and

  1. Article

    Open Access

    Correction: Economic burden of chronic migraine in OECD countries: a systematic review

    Alyaa Eltrafi, Sunil Shrestha, Ali Ahmed, Hema Mistry… in Health Economics Review (2023)

    Download PDF (927 KB) View Article

  2. Article

    Open Access

    Economic burden of chronic migraine in OECD countries: a systematic review

    Chronic migraine (CM) is a significant neurological condition affecting a substantial portion of the global population. The economic burden of CM includes both direct healthcare costs and indirect costs result...

    Alyaa Eltrafi, Sunil Shrestha, Ali Ahmed, Hema Mistry… in Health Economics Review (2023)

    Download PDF (1123 KB) View Article

  3. No Access

    Article

    Autologous Chondrocyte Implantation with Chondrosphere for Treating Articular Cartilage Defects in the Knee: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Chondrosphere (Spherox) is a form of autologous chondrocyte implantation (ACI). It is licensed for repair of symptomatic articular cartilage defects of the femoral condyle and the patella of the knee with defe...

    Xavier Armoiry, Ewen Cummins, Martin Connock, Andrew Metcalfe… in PharmacoEconomics (2019)

  4. Article

    Open Access

    Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Open Access This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/

    Hema Mistry, Chidozie Nduka, Martin Connock, Jill Colquitt… in PharmacoEconomics (2019)

    Download PDF (498 KB) View Article

  5. No Access

    Article

    Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Pembrolizumab is an intravenously administered monoclonal antibody licensed for locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. This summary presents the perspective...

    Daniel Gallacher, Xavier Armoiry, Peter Auguste, Rachel Court… in PharmacoEconomics (2019)

  6. Article

    Open Access

    Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Venetoclax is licensed to treat relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL). As part of the Single Technology Appraisal (STA) ID944, the National Institute for Health and Care Excellence (...

    Hema Mistry, Chidozie Nduka, Martin Connock, Jill Colquitt… in PharmacoEconomics (2018)

    Download PDF (515 KB) View Article

  7. No Access

    Article

    Comparison of general practitioner records and patient self-report questionnaires for estimation of costs

    This study compared resource use data and estimated costs over a 12-month period, based on patient self-report questionnaires and general practitioner records. The level of agreement was measured by weighted κ...

    Hema Mistry, Martin Buxton, Louise Longworth… in The European Journal of Health Economics (2005)